Webinar | Women’s Nutrition: Nourishing Womanhood From Pregnancy To Menopause
11 September | 12 PM ET: Register Now
Webinar | Women’s Nutrition: Nourishing Womanhood From Pregnancy To Menopause
11 September | 12 PM ET: Register Now
IPR2026-00256 · U.S. Patent 11,014,982 · Anti-TNF Antibodies for the Treatment of Active Ankylosing Spondylitis — A coordinated biosimilar consortium positions the PTAB as the final arbiter of Janssen's core evergreening tool by surfacing its own undisclosed clinical protocol as the missing prior art.
| Field | Detail |
|---|---|
| Case Number | IPR2026-00256 |
| Patent No. | U.S. 11,014,982 ("the '982 patent") |
| Patent Title | Anti-TNF Antibodies, Compositions, and Methods for the Treatment of Active Ankylosing Spondylitis |
| Petitioner | Accord BioPharma, Inc.; Intas Pharmaceuticals Ltd.; Bio-Thera Solutions, Ltd. |
| Patent Owner | Janssen Biotech, Inc. |
| Priority Date | February 7, 2017 |
| Targeted Claims | Claims 1–10 (antibodies with HC: SEQ ID NO:36 and LC: SEQ ID NO:37) |
| Petition Filed | March 20, 2026 |
| Lead Expert (Petitioner) | Dr. Roy M. Fleischmann (Ex-1005) — Master of the ACR, designated "World Expert" by Expertscape |
This filing is categorized as an Evergreening Counter-Strike. The trigger is not a generic biosimilar IP clearance review — it is a targeted dismantling of a patent the Petitioner alleges was procured through a deliberate non-disclosure scheme designed to extend the SIMPONI ARIA monopoly.
The Petition characterizes the '982 patent as the "invalid fruit of Janssen's scheme to hide key prior art from the examiner to evergreen its patent protection for SIMPONI ARIA and frustrate competition by lower-cost biosimilar products."
The Petitioner asserts Janssen secured the '982 patent by withholding its own long-standing clinical protocol (NCT873-V24) from the USPTO, effectively patenting a "novel" method that Janssen itself had already placed in the public domain.
Three Strategic Indicators
| Dimension | Detail |
|---|---|
| Therapeutic Class | Anti-TNFα monoclonal antibody (golimumab) |
| Molecule Identity | Heavy Chain: SEQ ID NO:36 · Light Chain: SEQ ID NO:37 |
| Reference Product | SIMPONI ARIA® (golimumab IV) |
| Indication Claimed | Active Ankylosing Spondylitis (AS) |
| Manipulative Steps | IV infusion of 2 mg/kg at Weeks 0, 4, and q8w thereafter — 30±10 min infusion in 0.9% saline (per PI2013-Aria) |
| Claimed "Results" | ASDAS <1.3 (inactive disease) at Wk 2/4; mean change in BASFI, BASMI, SF-36 PCS/MCS, ASQoL at Wk 16; ≥65% ASAS20 at Wk 16 |
| Patent Family Driver | NCT02186873 trial — same clinical protocol underlying Example 9 of the patent |
The claims do not introduce a new drug, a new route, a new formulation, or a new dosing schedule — every manipulative step was already disclosed in NCT873-V24. The patent's novelty rests entirely on functional efficacy parameters that are inherent properties of the disclosed regimen.
The '982 patent currently serves as a legal barrier to lower-cost golimumab biosimilar entry in the Ankylosing Spondylitis (and indirectly PsA) markets. Invalidation removes the IV "convenience firewall" — the 30-minute infusion advantage that distinguishes SIMPONI ARIA from subcutaneous SIMPONI — and clears the path for Accord, Intas, and Bio-Thera to launch competing IV golimumab products. Industry-wide impact extends to other biosimilar entrants (Celltrion, Amgen) who would benefit from standardization of the 2 mg/kg IV regimen as a non-patentable industry norm.
Janssen has deployed a "Rolling Issuance" strategy across the golimumab IV franchise: a chain of continuations each carving a separate indication or efficacy parameter from the same underlying clinical dataset (NCT02186873). The '982 is the lead asset; the rest of the family is a parallel attack surface.
| Patent | Indication / Carve-out | Parallel IPR Challenge |
|---|---|---|
| U.S. 11,014,982 ('982) | Active Ankylosing Spondylitis (lead asset) | IPR2026-00256 (this case) |
| '020 Patent | Psoriatic Arthritis (PsA) | IPR2026-00257 |
| '824 Patent | Psoriatic Arthritis (PsA) | IPR2026-00258 |
| '566 Patent | Ankylosing Spondylitis (parallel) | IPR2026-00259 |
Because every continuation rests on the same NCT873-V24 clinical record and the same "results-as-limitations" prosecution theory, a final written decision against the '982 creates terminal collateral estoppel risk for the entire AS/PsA portfolio.
The '982 patent's allowance was secured through a pivot to "surprising results" after a prima facie obviousness rejection. The Petitioner's central thesis is that the Examiner's record was fatally incomplete — Janssen's own clinical protocol was withheld.
Prosecution Timeline
Examiner Record vs. Reality
| Examiner's Limited Record (Inman / Doyle) | The Reality of NCT873-V24 |
|---|---|
| Concluded no prior art taught IV administration specifically for Ankylosing Spondylitis | Explicitly discloses IV administration of 2 mg/kg golimumab for active AS patients |
| Believed the SC→IV transition for AS was not suggested in the art | Establishes a public protocol for the exact IV dose and frequency claimed |
| Assumed the dosing schedule (Wks 0, 4, q8w) was a novel clinical discovery | Documents the identical schedule more than a year before the patent was filed |
Janssen told the USPTO results were "surprising" versus SC data, while telling the FDA in the CDER Review (Ex-1034) that "data directly comparing [IV vs. SC] are not available" — making the superiority claim legally and factually unsupportable.
Independent claims 1, 4, and 7 define the method through administration of golimumab (HC: SEQ ID NO:36 / LC: SEQ ID NO:37). Each claim couples identical manipulative steps with different efficacy parameters — the entire patentability case rests on whether those parameters carry weight.
| Claim | Manipulative Steps (Administration) | Claimed Results (Efficacy Parameters) | Vulnerability |
|---|---|---|---|
| 1 | IV infusion of antibody (SEQ ID NO:36 / 37) — 2 mg/kg at Wks 0, 4, q8w | ASDAS inactive disease (<1.3) at 2 or 4 weeks | High |
| 4 | IV infusion of antibody (SEQ ID NO:36 / 37) — identical regimen | Mean change from baseline at Wk 16: BASFI (−2.4±2.1), BASMI (−0.4±0.6), SF-36 PCS (8.5±7.5), SF-36 MCS (6.5±9.1), or ASQoL (−5.4±5.0) | High |
| 7 | IV infusion of antibody (SEQ ID NO:36 / 37) — identical regimen | ≥65% of patients achieve ASAS20 at Wk 16 | High |
| 8 | Dependent — same manipulative steps | Efficacy sub-thresholds (functional) | Medium |
| 2, 3, 5, 6, 9, 10 | Composition / dosing dependents — "safe and effective amount," "pharmaceutically acceptable carrier" | Filled by PI2013-Aria / PI2015-Simponi (0.9% saline, 30±10 min infusion) | Low (formality) |
Under Bristol-Myers Squibb v. Ben Venue, Baxter v. Millennium Biologix, and Fresenius-Kabi v. Cubist, "intended results" do not modify the manipulative steps. The recited ASDAS / ASAS20 / BASFI parameters describe consequences of an identical regimen — they are inherent properties, not limitations.
Ground 1 — Anticipation by NCT873-V24 (§ 102)
NCT873-V24 (publicly available October 27, 2015) anticipates claims 1–10 because it discloses every manipulative element. Critically, the protocol is the same clinical trial described in Example 9 of the '982 patent. Treatment Group 2 matches the claimed 2 mg/kg weight-based dose and Wks 0, 4, q8w frequency. Because the protocol and patent describe the identical study, the claimed efficacy results are inherent to the prior art method.
Ground 2 — Obviousness: NCT873-V24 + PI2013-Aria (§ 103)
A POSA would be motivated to combine the AS clinical protocol with the existing SIMPONI ARIA label for RA. The label provides the missing tactical details — 30-minute infusion time and saline diluent — for the same drug, same dose, same manufacturer.
Ground 3 — Comprehensive Obviousness (multi-reference) (§ 103)
| Reference | Technical Contribution | Strategic Relevance |
|---|---|---|
| Van der Heijde | ASDAS inactive disease scores for SC golimumab | Establishes ASDAS as a standard, predictable clinical metric for AS |
| Inman | Rapid ASAS20 response for SC golimumab in AS | Establishes golimumab's rapid onset of action in AS |
| Weinblatt | IV golimumab efficacy in RA at 2 weeks | Bridges SC and IV data to establish predictable 2-week IV onset |
Rebuttal of Secondary Indicia
Rebuts the "surprising" nature of ASDAS <1.3 as a predictable outcome; argues efficacy at 2/4 weeks is a "difference in degree, not kind" (citing In re Huang); and testifies that PK modeling made IV trough levels matching/exceeding SC levels entirely predictable to a POSA.
| D. Del. Case | 1:26-cv-00222 |
| D. Del. Status | Stipulated dismissal w/o prejudice (Mar 17–18, 2026) |
| Petition Filed | March 20, 2026 |
| Forum Shift | Validity battle moved to PTAB (preponderance standard) |
| Petitioner | Accord BioPharma |
| Family Tie | Same NCT02186873 clinical record |
| Theory | Same "results-as-limitations" attack |
| Estoppel Posture | Linked to '982 outcome |
| Petitioner | Accord BioPharma |
| Family Tie | Same prosecution-history pivot |
| Theory | Functional efficacy parameters |
| Estoppel Posture | Linked to '982 outcome |
| Petitioner | Accord BioPharma |
| Family Tie | Direct parallel to '982 AS challenge |
| Theory | NCT873-V24 anticipation / inherency |
| Estoppel Posture | Highest collateral exposure to '982 FWD |
The "patent dance" began on September 9, 2025 with a confidentiality agreement. Janssen's D. Del. complaint (Mar 3, 2026) was filed under seal because it contained BPCIA-exchanged information. The stipulated dismissal of the '982 from D. Del. narrows the district court trial to patents less exposed to "printed publication" attacks while preserving Janssen's right to re-assert if the patent survives PTAB.
| Stakeholder | Role | Products at Risk LOCKED | If Patent Survives ⚠ | If Patent Falls |
|---|---|---|---|---|
Accord BioPharma (Petitioner) Biosimilar Challenger |
Petitioner | View detailsClick to unlock |
Launch path cleared; immediate freedom-to-operate for proposed biosimilar | |
Janssen Biotech (Patent Owner) Innovator / Market Protector |
Owner | View detailsClick to unlock |
Portfolio devaluation; entire continuation strategy weakened | |
Other Biosimilar Players Celltrion, Amgen |
Potential Entrants | View detailsClick to unlock |
Industry-wide relief; 2 mg/kg IV regimen standardized as non-patentable norm | |
Healthcare Payers & AS Patients End Users / Funders |
Indirect | View detailsClick to unlock |
Faster access to lower-cost biosimilar treatments for active AS |
Accord explicitly positions this IPR as the "industry's firewall" against evergreening. Because the challenged claims cover the specific efficacy results a biosimilar must achieve to prove highly-similar status, there is no design-around. Biosimilar developers must either win this IPR or wait out the patent.
The strongest settlement window opens between institution and the patent owner response. After the Board confirms the NCT873-V24 evidentiary record on the docket, Janssen's leverage to settle on favorable terms across the four-patent family collapses.
Fintiv Institution Likelihood — All Four Coordinated Petitions
Biosimilar competitors and payers should track the institution decision for IPR2026-00256 in the September 2026 window. Institution on Ground 1 (Anticipation by NCT873-V24) would functionally pre-decide the parallel '566 challenge and create immediate settlement pressure across the '020 / '824 PsA continuations.
